FTC approves Amneal’s $1.45bn acquisition of Impax
11-07-2018
FTC antitrust charges against Impax dismissed
25-05-2018
Impax to divest 10 products amid acquisition by Amneal
30-04-2018
Purdue Pharma sues Amneal over OxyContin
03-03-2017
Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Amneal, Impax, generics, M&A, Chirag Patel, Paul Bisaro
